Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in type 2 diabetes mellitus with non-alcoholic fatty liver disease
IRCT20191209045671N3Phase 3Completed
- Sponsor
- Semnan University of Medical Sciences
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of empagliflozin in type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Semnan University of Medical Sciences. Primary endpoints: Blood glucose, Triglyceride and 3 more. Started May 2024; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on IRCT20191209045671N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20191209045671N3.